Matthew Galsky, MD
Matthew Galsky, MD, is a professor of medicine, director of genitourinary medical oncology, and co-director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and associate director for translational research at The Tisch Cancer Institute.
Articles
Safety and Efficacy Data from CheckMate 274 on Adjuvant Nivolumab Therapy for Patients with MIBC
January 23rd 2023Matthew Galsky, MD, explains safety and efficacy data from the CheckMate 274 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC, and highlights important data updates from recent conferences.
Phase II Trial Considers the Benefit of Switch Maintenance in Urothelial Cancer
July 24th 2019Matthew Galsky, MD, discusses how the phase II HCRN GU14-182 study helps to define the role of switch maintenance therapy in patients with urothelial cancer. The study looked at maintenance with pembrolizumab versus placebo following frontline chemotherapy in patients with metastatic urothelial cancer.
The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer
October 11th 2016Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.
